AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$EOLS

Evolus outlines $450M-$500M 2028 revenue target while reaffirming 2026 revenue of $330M-$337M (NASDAQ:EOLS)

Evolus (EOLS) set a 2028 revenue target of $450M-$500M, reaffirming 2026 revenue guidance of $330M-$337M. CEO David Moatazedi highlighted four consecutive quarters of positive adjusted EBITDA and portfolio growth.

Original reporting
seekingalpha.com
Published Nov 5, 2026, 3:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$EOLS
Neutral
high confidence
Mentioned
$EOLS
Relevance
8/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$EOLSNeutralHigh
01

Why it matters

The guidance update is the first public disclosure of Evolus' forward revenue outlook, providing new data for valuation and trading decisions.

02

Market read

Fresh guidance can move the stock as investors adjust expectations for growth and profitability.

03

What to watch

Potential upcoming product launches or international expansion could offset the modest revenue targets.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Evolus (NASDAQ:EOLS) is a medical aesthetics company known for its Botox competitor, Jeuveau.

Company-level read

Ticker impact

$EOLSNeutralHigh confidence
Context

Evolus disclosed its 2028 revenue target of $450M-$500M and reaffirmed 2026 revenue of $330M-$337M, a fresh guidance update.

Expected impact

potential downside pressure as analysts compare the guidance to prior expectations and market forecasts

Evidence & confidence

Guidance is the first public disclosure of these figures; traders will reassess valuation models, likely adjusting price lower if the targets are seen as modest.

Market effects

Sector

Sets a benchmark for the aesthetic medicine sector, potentially influencing peer valuations.

Regional

Limited to U.S. biotech and consumer‑health investors.

Global

Minimal global impact beyond sector peers.

Counterpoint

What could challenge this read

If the market overreacts to the guidance, a contrarian could view the numbers as a floor and look for upside on execution.

Key entities

  • Company
    Evolus

    Medical aesthetics firm providing injectable treatments.

Read at source← All news

StoryEvolus reports Q3 results, cuts expense guidance and reaffirms 2026‑2028 revenue targets

Also covered by

1 outlet

Related articles

$EOLSMed

What Evolus (EOLS) Said on Its Q3 Earnings Call

Evolus (EOLS) cut its full-year non-GAAP operating expense guidance to $210M-$213M and reaffirmed 2028 revenue targets of $450M-$500M with adjusted EBITDA margins of 13%-15%. The company expects FDA approval for Sculpt in Q4 2026 and a 2027 launch. Evolysse and Estyme gel lines are projected to contribute 10%-12% of full-year revenue. Evolus added over 500 purchasing accounts, bringing its total to over 19,000.

finance.yahoo.com
$EOLSMed

Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA…

Evolus, Inc. (EOLS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook • Global Net Revenue of $78.0 Million for the Third Quarter of 2026, an Incre

SEC EDGAR 8-K
$EOLSMed

Evolus (EOLS) Shares Fall After FDA Warning on Jeuveau Instagram

Evolus Inc (EOLS) shares fell after the FDA issued a warning over a misleading Instagram post about its product Jeuveau. The company must submit a corrective action plan within 15 days. Evolus's P/S ratio is 1.49, below its historical median, and it has a GF Score of 74/100. Insiders have sold $1.8 million in shares over the past year. Jeuveau accounts for over 90% of the company's revenue, which totaled $316.5 million over the trailing twelve months.

gurufocus.com
$EOLSHigh

FDA Flags Evolus (EOLS) for Misleading Jeuveau Promotion on Inst

The FDA warned Evolus (EOLS) for misleading Jeuveau promotion on Instagram, citing public health risks. Evolus's P/S ratio is 1.49, below its historical median of 3.2x, reflecting market uncertainty. The company has a GF Score of 74/100, with strong growth but weak profitability and financial strength. Insiders sold $1.8M in shares over the past year, while institutional investors show mixed interest.

gurufocus.com